"Support for Contrave is less about how good this particular drug combination is (it's modestly effective and has some toxicity), and more about how bad the overall state of pharmacotherapy for weight management is," said David L. Katz, MD, MPH, director of the Yale University Prevention Research Center. "The FDA committee's decision can be justified by invoking the 'any port in a storm!' clause."
http://www.medpagetoday.com/PrimaryCare/Obesity/24049
|
